Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

38.80 +0.18 (+0.47%)
Official Closing Price Updated: 6:30 PM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product? ↗
The drugmaker badly needs more clinical wins. 
Via The Motley Fool
News headline image
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? ↗
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved. 
Via MarketBeat
News headline image
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up? ↗
Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits. 
Via MarketBeat
Topics Intellectual Property Lawsuit
News headline image
Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗
The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off. 
Via The Motley Fool
News headline image
Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems ↗
Novo Nordisk is dealing with headwinds, but was its name really one of the big problems? 
Via The Motley Fool
News headline image
Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy? ↗
Semaglutide will start losing patent protection in the near future. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction ↗
Novo Nordisk A/S (NYSE:NVO) outlined an updated strategy at its Capital Markets Day centered on diabetes and obesity, expansion into blood and endocrine disorders, liver disease and cardiovascular... 
Via MarketBeat
News headline image
Why Novo Nordisk Stock Just Crashed ↗
No one expects a lot of growth from Novo Nordisk anymore -- not even Novo Nordisk itself. 
Via The Motley Fool
News headline image
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. ↗
The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors. 
Via The Motley Fool
News headline image
This Trend is Excellent News for Eli Lilly and Its Investors ↗
Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market. 
Via The Motley Fool
News headline image
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗
The company is still looking to bounce back after the beating it took in recent years. 
Via The Motley Fool
Topics Economy
News headline image
Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything ↗
The drugmaker has a lot riding on continued clinical progress. 
Via The Motley Fool
News headline image
3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026 ↗
These stocks have been struggling lately, but they could be underrated buys in the long run. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst ↗
Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind. 
Via The Motley Fool
News headline image
Could This New Opportunity Be Worth Billions for Novo Nordisk? ↗
The worst may be in the rearview mirror for the drugmaker. 
Via The Motley Fool
News headline image
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? ↗
Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease. 
Via The Motley Fool
News headline image
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗
This company aims to serve a market heading toward $100 billion. 
Via The Motley Fool
News headline image
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? ↗
Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 of the Best Growth Stocks to Buy for Less Than $100 Right Now ↗
Netflix, Uber, and Novo Nordisk are all excellent, undervalued stocks to buy today. 
Via The Motley Fool
News headline image
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗
The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions. 
Via The Motley Fool
News headline image
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗
Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company. 
Via The Motley Fool
News headline image
2 Stocks Down 8% or More That Are Screaming Buys Right Now ↗
You might regret ignoring these companies at current levels. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗
Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate. 
Via The Motley Fool
News headline image
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly? ↗
Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space. 
Via The Motley Fool
News headline image
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗
Duquesne Family Office has beefed up its healthcare holdings. 
Via The Motley Fool
News headline image
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can ↗
Could this little-known biotech be a hidden gem? 
Via The Motley Fool
News headline image
2 Biotech Stocks Shaping Up for Major Breakouts ↗
Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts. 
Via MarketBeat
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.